The Fli-1 protein is a member of the ets proto-oncogene family, whose overexpression is a consequence of Friend murine leukemia virus (F-MuLV) integration in Friend erythroleukemic cells. We present evidence that Fli-1 and the retinoic acid receptor (RARa) can reciprocally repress one another's transcriptional activation. Overexpression of Fli-1 inhibits the retinoic acid-induced activation of genes carrying a functional retinoic acid response element (RARE). Conversely, RARa is able to repress Fli-1-mediated transcriptional activation. Transfection analysis of RARa and Fli-1 mutants in cultured cells demonstrate that the DNA binding domain of RARa and the N-terminal region of Fli-1 are required for repression. Gel retardation analysis demonstrates that RARa cannot bind to the Fli-1 binding site in the E74 promoter and the expression of Fli-1 does not aect RARa binding to DNA. Furthermore, the data suggest an indirect interaction between Fli-1 and RARa mediated by a`bridging' factor(s) present in nuclear extracts from RM10 erythroleukemia cells. Fli-1 also interferes with the action of receptors for thyroid or glucocorticoid hormone in several hematopoietic cell lines. The RAinduced dierentiation and decrease of cell proliferation was blocked in myeloblastic leukemia HL-60 cells overexpressing the N-terminal region of Fli-1 at physiological concentrations of RA. These data suggest that accumulation of Fli-1 can oppose the transcriptional activity of hormone receptors in hematopoietic cells.
Introduction
The regulation of several developmental and metabolic pathways is known to be in¯uenced by a variety of hormones and growth factors (reviewed in Blomho, 1994; Chambon, 1994; Sporn et al., 1994; Scheibe et al., 1991 and Wagner, 1992) . The hormones exert their regulatory eects by binding to a superfamily of intracellular receptors, which are direct modulators of gene transcription. The receptors for retinoic acid (RARs), glucocorticoid (GR), and thyroid hormone (T 3 R) are members of this family, and mutational analysis have identi®ed functional domains responsible for transcriptional activation, receptor dimerization, hormone binding, and DNA binding (for reviews, see Beato, 1989; Evans, 1988; Green and Chambon, 1988; Kastner et al., 1994; Leid et al., 1992; Mangelsdorf et al., 1994) . Three dierent RAR types, designated as RARa, b, and g, have been identi®ed as well as several receptor isoforms, diering primarily in the N-terminal coding region (Chambon et al., 1991; de TheÂ and Dejean, 1991; Linney, 1992; Pfahl et al., 1991) . The RARs can modulate the transcription of target genes by interacting with cis-acting DNA RA response elements (RAREs). The RARb2 gene, coding for the RARb2 receptor isoform, contains an RARE in its promoter region (b2RARE). One of the early events following the exposure of many cells to RA is the strong induction of RARb2 gene expression mediated by activated receptor (de TheÂ et al., 1990; Sucov et al., 1990) .
During hematopoiesis, alteration or disruption of regulatory signals from hormone nuclear factors and membrane receptors can result in uncontrolled proliferation of cells that lose the capability to develop to a dierentiated phenotype. The synergistic action of abnormal membrane receptors and nuclear factors are frequently the reason for the establishment of leukemogenesis (Sap et al., 1986; Weinberger et al., 1986) . Concurrent disregulation of cellular and nuclear signals are also involved in the establishment of retrovirally-induced erythroleukemias. The erythroleukemias induced by either the replication-defective spleen focus forming virus (SFFV) or the replicationcompetent murine leukemia virus (F-MuLV) are multistage malignancies (reviewed in . They are characterized by disregulated proliferation of proerythroblasts resulting from the direct interaction of gp55 or gp70 glycoproteins with the erythropoietin receptor which eliminates the dependency of erythroid cells for the endogenous hormone and induces a mitogenic signal in the cells (Li and Baltimore, 1991; Li et al., 1990) . Later stages of these erythroleukemias are characterized by the appearance of malignant cell clones that have lost the capacity to dierentiate into mature blood cells. They require additional events, including the activation and overexpression of oncogenes, such as PU.1/spi-1 (Klemsz et al., 1990; Moreau-Gachelin et al., 1988 , 1989 Paul et al., 1991) or¯i-1 (Ben-David and Ben-David et al., 1990) , by proviral integration. The precise contribution of the deregulated expression of Fli-1 and PU.1/Spi-1 to the erythroleukemic process is unknown. Since the activation of these oncogenes occur as a late event of the disease the overexpressed proteins appear to be involved in blocking the erythroid dierentiation and maintaining the cells in a proliferative stage. In fact, recent data suggest at least for PU.1/Spi-1 a major role in the selfrenewal of proerythroblastic cells and terminal differentiation of erythroblasts (Delgado et al., 1994; Rao et al., 1997; Schuetze et al., 1993) .
The Fli-1 protein is a member of the Ets family of transcription factors and expressed in several hematopoietic cells Klemsz et al., 1993) . Other members of the Ets family are c-Ets-1, Ets-2, Erg, Elk-1, PU.1/Spi-1, Elf-1, GABP-a, PEA-3, Sap-1 and Sap-2 (for reviews, see Janknecht and Nordheim, 1993; Wasylyk et al., 1993; Bassuk and Leiden (1997) . They share homology in a 85-amino-acid region, the Ets domain, which is responsible for sequence-speci®c binding to DNA Reddy and Rao, 1990; Reddy et al., 1987) . DNA sequences bound by several Ets family members have been analysed and found to include a central GGA core sequence (for a review, see Seth et al., 1992) . Fli-1, PU.1/Spi-1, c-ets-1 (Leprince et al., 1983; Nunn et al., 1983) , and v-ets (Golay et al., 1988; Metz and Graf, 1991; Nunn and Hunter, 1989) are implicated in retrovirus-mediated leukemogenesis. Fli-1 is rearranged and overexpressed in 75% of erythroleukemias induced in newborn mice by F-MuLV and the human homolog of¯i-1 is rearranged in tumors of the Ewing family (Delattre et al., 1992) , indicating that Fli-1 is involved in malignancies in both humans and mice (Lessnick et al., 1995; May et al., 1993) . Studies in transgenic mice overexpressing Fli-1 suggest that Fli-1 is an important regulator of lymphoid cell function (Zhang et al., 1995) . Fli-1 is rapidly down-regulated during murine macrophages dierentiation and normal lymphocyte activation Mao et al., 1994) , suggesting that Fli-1 may interfere with processes required for terminal dierentiation. It is believed that RARa and T 3 R are involved in the modulation of dierentiation in erythroid cells and that RA and T 3 act directly on erythroid progenitors (Schroeder et al., 1992) . Thus, the oncogenic potential of deregulated Fli-1 may in part be related to its ability to interfere with the action of RA and steroid hormones.
In the present study, we have searched for a functional interference between Fli-1 and retinoic acid or steroid hormone receptors that might modify target gene transcription and cell dierentiation. We describe that Fli-1 represses RARa-mediated induction of the RARb2 promoter and of constructs containing natural RAREs, such as the apolipoprotein AI-RARE. Conversely, RARa represses Fli-1-induced transcriptional activity of reporter constructs containing a single Fli-1 DNA binding site of human glycoprotein IIb or four copies of the Fli-1 binding site in the E74 promoter. Fli-1 also represses ErbA/T 3 Ra-and GRmediated transcriptional activation. Transfection analysis of RARa and Fli-1 mutants reveals that the Nterminal domain of Fli-1 and DNA binding domains of RARa and GR are required for the observed repression. Gel mobility shift experiments demonstrate that RARa cannot bind to the Fli-1 binding site in the E74 promoter and the expression of Fli-1 does not aect RARa binding to DNA. In the presence of nuclear extract prepared from RM10 erythroleukemia cells overexpressing Fli-1 and RARa, a slowly migrating complex was formed which contains at least Fli-1 and RARa. Our results suggest an indirect interaction between the two proteins. The interference between Fli-1 and steroid hormone/vitamin receptors was observed in several hematopoietic cell lines. Finally, transfection of myeloblastic leukemia HL-60 cells with a construct expressing the N-terminal region of Fli-1 was found to inhibit RA-induced differentiation and decrease of cell proliferation at physiological concentrations of RA.
Results
Fli-1 represses RAR-mediated activation of RARb2-LUC and synthetic RA-responsive elements Using information derived from the murine Fli-1 cDNA sequence , two primers were designed to amplify a fragment from a Jurkat T cell cDNA library. With the obtained PCR fragment as a probe, the same library was screened and the longest cDNA insert from the positive phage clones was subcloned and sequenced. The 1823 bp cDNA sequence which represented the human homologue of murine Fli-1 had an open reading frame of 452 amino acids. Fli-1 protein obtained by in vitro translation of this cDNA had a molecular weight of *52 kDa (data not shown), which is consistent to the predicted size.
Comparison of human and murine Fli-1 showed a homology of 90% at the nucleotide level and of 97% at the deduced amino acid level.
During transfection studies that were designed to study transcriptional activation properties of Fli-1, we found that the addition of Fli-1 expression vector (Figure 1a ) inhibits the RA-induced transcription of the RARb2 promoter (de TheÂ et al., 1990; Homann et al., 1990; Sucov et al., 1990) . The RARb2 reporter plasmid was constructed containing 5 kb of sequence upstream of the RARb2 transcription start site fused to the luciferase reporter to generate RARb2-LUC. RARb2-LUC was cotransfected with increasing amounts of Fli-1 expression plasmid in the presence or absence of RA. The Fli-1 protein inhibited RAinduced reporter activity in a concentration-dependent manner (Figure 1a , compare lane 1 with lanes 2 ± 5). The promoterless pXP2 parental plasmid was not aected by cotransfection with Fli-1 expression vector (lanes 6 and 7), demonstrating that the inhibitory eect was not the result of toxicity caused by exogenous Fli-1 protein. RM10, a CML erythroleukemic blast crisis cell line, was used in this experiment because Fli-1 is not expressed in these cells .
To determine whether this inhibitory eect was caused by interference of Fli-1 with activated RARs or with other factors interacting with the RARb2 promoter, we performed additional transfection assays using the (b2RARE) 3 -TKLUC reporter plasmid (de TheÂ et al., 1990) . This reporter retains three copies of the RA response element (RARE) located in the RARb2 promoter. We cotransfected Fli-1 and RARa expression plasmids into RM10 cells and asked whether Fli-1 is able to inhibit RAR-mediated activation of (b2RARE) 3 -TKLUC. As shown in Figure 1b , RARa strongly induced the reporter plasmid activity in RM10 cells upon the addition of RA (Figure 1b, lane 2) . Induction of luciferase activity To investigate whether Fli-1-mediated repression is restricted to the b2RARE, we analysed the Fli-1 eect on an additional native RA-responsive element, the apolipoprotein AI (ApoAI)-RARE (Ladias and Karathanasis, 1991). The ApoAI-RARE is localized between 7214 and 7192 and contains a direct repeat and a third repeat of a speci®c DNA binding motif (Rottman et al., 1991) . The activity of ApoAI-TKLUC was induced by RARa in the presence of RA ( Figure  1b , lane 5) and repressed by expression of Fli-1 (lane 6). The expression of control plasmid TKLUC was not in¯uenced by either expression of Fli-1, RARa, or RA treatment (lanes 7 and 8). Together our data show that RA-dependent transactivation of reporter plasmids containing RAREs can be repressed by Fli-1.
Repression of Fli-1 transcriptional activation by RARa
The ability of Fli-1 to interfere with RA action suggests that Fli-1 can function as a negative regulator of RA-dependent transactivation. We next decided to investigate whether the reverse may be also possible. It has been shown, that the Fli-1 protein binds the GGA sequence of the E74 promoter Urness and Thummel, 1990) and acts as transcriptional activator in cotransfection studies Zhang et al., 1993) . Therefore, we transfected a chimeric reporter construct, (E74) 4 -TKLUC, that carries four E74 sites upstream of the TK promoter into Fli-1-negative RM10 cells. The function of this promoter was strongly dependent upon Fli-1 activation. As shown in Figure 2 , the (E74) 4 -TKLUC reporter plasmid has a low basal activity which was not aected by RA (lane 1). The activity of this plasmid was stimulated by the cotransfection of Fli-1 expression vector (lane 2). Interestingly, this induction was reduced in RA-treated cultures probably due to the activation of endogenous RAR receptor. The presence of RA and exogenous RARa resulted in a potent repression of this induction in a hormone concentration-dependent manner (lanes 3 ± 5). The extent of repression increased with the amount of exogenous RARa added. Under similar conditions, the activity of the control TKLUC plasmid was not altered by RA (lane 6), nor changed by RARa and Fli-1 in the presence or absence of RA (lane 7). In addition, the activity of control plasmid TKLUC was not altered by either RARa (Figure 1b, lane 7) or Fli-1 alone ( Figure  3b , lane 9).
To check whether the eect of RARa was speci®c to Fli-1 dependent promoters, we tested the activity of the Sp1-TKLUC construct, which contains a Sp1 binding site (Dynan and Tjian, 1983) but does not contain a Fli-1 site. The Sp1-TKLUC reporter activity was not altered by Fli-1 (lane 9). The activity of this promoter a b Figure 1 Fli-1 represses RAR-mediated induction. (a) RARb2-LUC reporter plasmid was transfected with increasing amounts of plasmid expressing Fli-1 into RM10 cells. The numbers indicate the amount of transfected plasmid DNA in mg. The pXP2 control plasmid was cotransfected with 1.5 mg of expression plasmid. The cells were either untreated (black bars) or treated (stippled bars) with RA (50 nM). Transcriptional activity was determined with endogenous RAR activity present in these cells. Transfection eciency was normalized by cotransfecting pRSV-hGH, and relative light units were normalized on the basis of the amount of growth hormone released into the culture medium. (b) Activity of reporter constructs (b2RARE) 3 -TKLUC, ApoAI-TKLUC, and control plasmid TKLUC was analysed in RM10 cells cotransfected with plasmids expressing RARa, Fli-1 or DFli-1 lacking the Fli-1 coding region. Where indicated with 7, no expression plasmid was cotransfected, where indicated with +, 0.5 mg of expression plasmids were cotransfected. The results in Figure 1 correspond to the average of four independent experiments was also not aected by expression of exogenous ligand-activated receptor (lane 10). Taken together, these data indicate that repression of transcriptional activation by RARa is dependent on the presence of a Fli-1 binding site.
The N-terminal part of Fli-1 is required for repression of RARa activity
To de®ne regions of the Fli-1 protein that are important for repression of RAR-mediated activation, we tested Fli-1 and a series of mutant Fli-1 proteins (see Figure 3a) cotransfected with RARa for their ability to repress (b2RARE) 3 -TKLUC activity. All mutants were well-expressed in similar amounts and localized to the nucleus (data not shown). As shown in Figure 3b , the RA-responsive construct was induced *70-fold after the addition of RA. This induction was repressed when Fli-1 expression vector encoding wildtype Fli-1 was cotransfected with (b2RARE) 3 -TKLUC (Figure 3b , compare lanes 1 and 2). Deletion of the Fli-1 DNA binding domain and subsequent ligation of the Fli-1 fragment to an SV40 nuclear translocation signal (named SV40LTFli-1Dets) (Kalderon et al., 1984) did not alter the repression pattern of the Fli-1 protein (lane 3). A mutant containing a point mutation (W-321?R) in the DNA binding region named Fli-1W321R, which abolishes Fli-1 DNA binding activity (Bailly et al., 1994) was also tested. This mutant was found to be as active in repressing reporter activity (lane 4) as wild-type Fli-1 or SV40LTFli-1Dets. In contrast, deletions of the N-terminal region (e3'Fli-1 and 3'Fli-1) abolished the ability of the mutant proteins to repress (b2RARE) 3 -TKLUC activity (compare lane 1 with lanes 5 and 6). In addition to these mutants, we constructed a mutant fusion protein containing the N-terminal 276 amino acids of Fli-1 and the SV40 nuclear localization signal (SV40LT5'Fli-1). In transfection assays, this mutant construct was at least as eective in repressing reporter activity as the wild-type Fli-1 (lane 7). The activity of the control plasmid TKLUC was not altered by overexpression of Fli-1 (lanes 8 and 9). These results indicate that the Nterminal region of Fli-1 containing the amino-terminal transactivation domain is important for repression of RARa-mediated transcriptional activation. To gain further insight into the mechanism of repression and to de®ne regions of the receptor involved in the repression, we constructed RARa mutants ( Figure 4a ) and analysed their ability to repress (E74) 4 -TKLUC activity. In this experiment RM10 cells were cotransfected with Fli-1 expression plasmid and treated with RA. As shown in Figure 4b , the (E74) 4 -TKLUC construct was induced *26-fold by expression of Fli-1 (lane 1). This induction was repressed by cotransfection with RARa expression plasmid (lane 2). The carboxy-terminal truncation mutant RARaDEF, that lacks the hormone binding domain, exhibited a reduced repression activity ( Figure  4b , lane 3). The amino-terminal deletion mutant RARaDAB, lacking the A and most of the B region of the RARa receptor, showed slight RA-mediated repression (lane 4). These results indicate that, to some extent, the ligand binding domain and the amino terminus contribute to the repression of Fli-1-dependent activity. As demonstrated in Figure 4b , lane 5, deletion of the DNA binding domain (RARaDC) lead to a nearly complete loss of repression. Similarly, a construct containing a mutation in the ®rst cysteine in the ®rst zinc ®nger (Yu et al., 1991) that renders the RARa incapable of binding to DNA, did not show any repression (Thomas G Darby, unpublished observation). The importance of the RARa DNA binding domain is interesting because the E74 core recognition sequence shows no homology to RAREs (Beato, 1989; Evans, 1988; and does not bind RARs or steroid hormone receptors (Figure 7d ). However, the DNA binding domain alone appears not to be sucient for repression, since a mutant expressing only the C region did not show any repression (RARaDABEF, lane 6).
Although the DNA binding domain of RARa does not recognize the E74 site, we have demonstrated that the DNA binding region of the receptor is important for repression. We further investigated whether a change of target gene speci®city of the receptor effects the ability to repress. We constructed a mutant in which the RARa DNA binding domain had been replaced with the DNA binding domain of GR (mutant RAR-GR-RAR). This mutant was able to repress Fli-1 activity (lane 7) almost as eciently as RARa. These results show that substitution of the DNA binding domain of RARa with the DNA binding domain of a steroid hormone receptor did not alter repression activity indicating that target gene speci®city is not important for repression. Taken together, the data indicate that the DNA binding domain and to some extent the ligand binding and N-terminal domain are required for repression.
Fli-1 represses T 3 R-and GR-mediated transcriptional activation
The data shown above demonstrate that Fli-1 interferes with the action of RARa, but did not repress hormoneindependent promoters. To determine whether this inhibitory eect could be extended to other nuclear receptors, we cotransfected RM10 cells with Fli-1, T 3 R and GR expression plasmids, respectively. The cellular c-erbA proto-oncogene encodes the a form of T 3 R (Sap et al., 1986; Weinberger et al., 1986) . C-ErbA binds to a set of speci®c response elements and enhance transcription when activated by T 3 . As shown in Figure and Jameson, 1993) , containing two hormone response elements (PAL 2 ) in a TKLUC parental plasmid in the presence of c-ErbA expression plasmid (compare lanes 1 and 2). Cotransfection of Fli-1 expression plasmid inhibited T 3 -induced activation of the reporter construct (lane 3). As expected, the activity of this reporter construct was also repressed by SV40LT5'Fli-1 (lane 4), but not aected by the N-terminal deletion mutants e3'Fli-1 or 3'Fli-1 (lanes 5 and 6). Transfection of parental expression plasmid DFli-1 did not alter the induced transcriptional activity of the PAL 2 -TKLUC reporter in the presence of T 3 (lane 7).
GR binds to glucocorticoid response elements (GREs) and induces GRE-TKLUC reporter activity upon the addition of the synthetic glucocorticoid dexamethasone (DEX). Cotransfection with GR expression plasmid induced the activity of GRE-TKLUC construct in the presence of DEX, which was repressed by addition of Fli-1 expression plasmid ( Figure 5b , compare lanes 2 and 3). As shown above with activated T 3 R, hormone-mediated induction of the reporter construct was not repressed by a deletion mutant lacking the N-terminal region of Fli-1 (lane 4). Interestingly, other Ets proteins, such as c-Ets-1 (lane 5), Elf-1, or GABP-a (data not shown), were incapable of repressing GRE-TKLUC activity. Control plasmid DFli-1 has no repression activity on the GRE-TKLUC reporter in the presence of DEX (lane 6). Together these results indicate that the interference between Fli-1 and RARa can be generalized to other steroid hormone receptors.
Repression of Fli-1-responsive reporter plasmids in several hematopoietic cell lines
We further tested the steroid hormone/vitamin receptors for their ability to repress (E74) 4 -TKLUC or GPIIb-TKLUC reporter activity in HEL and JK-1 erythroleukemias, and Jurkat T-cell leukemia. These human hematopoietic cell lines express high levels of endogenous Fli-1 and in the case of Jurkat do not express PU.1/Spi-1 . The GPIIb-TKLUC reporter construct contains a speci®c Fli-1 DNA binding site of the human glycoprotein IIb (GPIIb) gene. It has been reported that Fli-1, but not PU.1/Spi-1 transactivates a human GPIb IIb promoter construct containing that site . Figure 6 , lane 1, shows that in Jurkat cells transfected with the control TKLUC plasmid only a basal luciferase activity was detected. However, the basal activity was strongly elevated in GPIIb-TKLUC transfected Jurkat cells possibly by endogenous Fli-1 (compare lanes 1 with 2, in the absence of RA). This induction was slightly reduced by the addition of RA probably due to the stimulation of endogenous RAR receptor (lane 2). In the presence of RA, the induced reporter activity was eciently repressed by activated exogenous RARa (lane 3). In RA-treated cultures, only a slight repression was detected with cotransfected DRARa control plasmid, lacking the RARa coding sequences due to the activated endogenous receptor (compare lanes 2 and 4). plasmid showed no repression activity (compare lanes 5 and 7). We also tested the reporter activity in K562, a CML erythroleukemic blast crisis cell line, which expresses only PU.1/Spi-1 but not Fli-1 protein Klemsz et al., 1993) . As expected, only a small basal activity of the GPIIb-TKLUC reporter construct was detected ( Figure 6 , lane 8). In the presence of exogenous Fli-1 transcription of the GPIIb-TKLUC construct was strongly elevated which was then repressed by activated endogenous RAR (lane 9) or addition of exogenous RARa (lane 10). Overexpression of PU.1/Spi-1 did not alter basal transcriptional activity of the reporter (lane 11), indicating that Fli-1 recognizes and transactivates this reporter through a Fli-1-speci®c binding site.
The results led us to explore the possibility that the interference is caused by competition for limiting common factor(s) that mediate the action of Fli-1 and hormone/vitamin receptors in the nucleus. We cotransfected K562 cells with RARa, wild-type Fli-1, and SV40LT5'Fli-1 expression vector. Repression of GPIIb-TKLUC reporter activity by RARa was relieved by further addition of an excess of SV40LT5'Fli-1 vector encoding the N-terminal region of Fli-1 (Figure 6 , compare lanes 10 and 12). Since this mutant protein does not contain the DNA binding domain of Fli-1, the data indicate that the abrogation of repression is not caused by the binding of mutant protein to the Fli-1 site. It also suggests that Fli-1 and RARa are not competing for a limiting common factor(s) that is necessary for induced target gene transcription.
Repression was observed also in HEL and JK-1 cells transfected with GPIIb-TKLUC or (E74) 4 -TKLUC reporter plasmids in the presence of activated RARa (Table 1) . Because of the speci®city of the DNA binding site, the GPIIb-TKLUC reporter construct was activated possibly by endogenous Fli-1 present in these cell lines which was then repressed by addition of exogenous RARa. Similarly, c-ErbA and GR repress reporter activity in the presence of ligand. Both, Fli-1 and PU.1/Spi-1, are capable of binding to the E74 site. 
2 3 4 5 6 7 c 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 (Figure 7c ) using the PAL (Nagaya and Jameson, 1993) and GRE sequence, respectively, as a probe. Fli-1 did not bind to the PAL or GRE probe (lanes 3) and did not alter the anity of the receptors to their DNA binding site (lanes 4). Since our in vivo results indicate that the DNA binding domain of RARa is required to repress Fli-1 activation of E74, we further tested whether or not RARa can bind to this element. The complex formed with in vitro translated Fli-1 and the E74 oligonucleotide (Figure 7d , lane 1) was recognized and supershifted by anti-Fli-1 antiserum (lane 5). Preimmune serum had no eect on the complex mobility (lane 4). Mobility of the Fli-1-E74 complex was unaected by addition of in vitro translated RARa (lane 3) and RARa did not bind the E74 probe (lane 2). To correlate the in vitro data with our in vivo results, EMSAs were performed using nuclear extract (NE) from RM10 cells (containing exogenous RARa and Fli-1, lanes 6 ± 11) and the E74 oligonucleotide. A slower mobility EMSA complex was formed (lane 6), which was recognized and shifted by anti-Fli-1 (lane 8) or anti-RARa antisera (lane 9) but not by preimmune serum (lane 7). The complex formation was competed by a 200-fold excess of unlabeled E74 oligonucleotide (lane 10), but was not competed by an excess of nonspeci®c oligonucleotide (lane 11) containing two Sp1 binding sites . Under our experimental conditions, the slower mobility complex was also detected using nuclear extract from HL-60 (lane 12) and K562 cells (data not shown) but was not detected with nuclear extracts from F9 teratocarcinoma (lane 13) and HeLa cells (lane 14). We could not detect binding of in vitro translated SV40LT5'Fli-1 mutant protein to E74 (lane 15) or the b2RARE sequence (T G Darby, unpublished observations). Taken together, these results show that expression of Fli-1 does not aect hormone/vitamin receptor binding to DNA and vice versa RARa does not bind to a Fli-1 site or aect Fli-1 binding to DNA. The data suggest that Fli-1 and not the Fli-1 site is the target for RARa mediated inhibition. They also suggest that there is no direct interaction between RARa and Fli-1 and that nuclear extract from at least two hematopoietic cell lines may contain a`bridging' factor(s) involved in complex formation mediating indirect interaction.
Overexpressed Fli-1 mutant can block RA-induced dierentiation and decrease of proliferation in myeloblastic leukemia cells
The myeloblastic leukemia HL-60 cell line consists of acute myeloblastic leukemia cells (Breitman et al., 1980) which expresses endogenous Fli-1 protein and TG Darby, unpublished observations) . Data obtained by EMSAs indicate that HL-60 cells contain a`bridging' factor(s) mediating the interaction between Fli-1 and RARs. Incubation with RA induces inhibition of cellular growth and differentiation and reduces HL-60 cell proliferation. To examine whether interference of Fli-1 with activated RARs plays a role in the early process of differentiation, we transiently transfected cells with the SV40LT5'Fli-1 and e3'Fli-1 constructs, respectively. Since the transfection eciency was estimated to be around 10% based on the transfection of a green uorescent protein expression construct we selected transfected cells using a technique described in Materials and methods (Chestnut et al., 1996) . The homogeneous population of transient transfected cells was then cultured in the presence or absence of 50 nM RA. Thymidine incorporation was determined as an index of cell proliferation at several dierent time points. Cells transfected with either the e3'Fli-1 construct or the parental plasmid alone had a signi®cantly reduced thymidine incorporation after 4 days of RA treatment compared with the controls which were cultured in the absence of RA (Figure 8a and b). No decline in thymidine incorporation was observed in cells transfected with the SV40LT5'Fli-1 construct over the same period of RA treatment. This result was con®rmed by the analysis of the number of cells present in the assay. Four days after addition of RA, the number of cells was signi®cantly lower when transfected with e3'Fli-1 or pSG5 compared with cells expressing mutant SV40LT5'Fli-1 (Figure 8c ). Similar results were obtained 6 days after transfection and treatment with 50 nM RA. A response of cells expressing mutant SV40LT5'Fli-1 to supraphysiological concentration of RA (50 mM) was measured at day 6. HL-60 cells can be induced to terminally dierentiate to granulocyte-like cells by incubation with physiological concentrations of RA (1 ± 100 nM) (Breitman et al., 1980) . In the presence of 50 nM RA, 
Discussion
Mouse Fli-1 and PU.1/Spi-1 are targets of insertional activation during the induction of erythroleukemia by the various strains of Friend erythroleukemia virus . This insertional activation and the interaction of the gp55 protein or gp70, a glycoprotein related to gp55 (Li and Baltimore, 1991) , with the erythropoietin receptor are understood as a causative event in Friend murine leukemia . Although viruses have not been found to be important in human erythroleukemia, the same genes including the Ets transcription factors may underlie the process of erythroleukemia formation. The expression of Fli-1 in the thymus and spleen of adult mice, the presence of DNA binding sites for Fli-1 in a number of lymphoid cell-speci®c genes (Hagman and Grosschedl, 1994; Leiden and Thompson, 1994) , and the development of immunological renal disease in¯i-1 transgenic mice suggests that Fli-1 plays a critical role in the regulation of both T and B lymphoid cell function (Zhang et al., 1995) . The reciprocal chromosomal t(11;22) translocation in Ewing's sarcoma and neuroepithelioma, which encodes the EWS-Fli-1 fusion protein (Delattre et al., 1992; Lessnick et al., 1995; May et al., 1993) indicates that Fli-1 is implicated in oncogenesis in mice and humans. During the analysis of the transcriptional activity of the Fli-1 gene product, we found a novel characteristic of this oncoprotein. Fli-1 can repress transcription of RA-responsive constructs, such as RARb2-LUC, (b2RARE) 3 -TKLUC and ApoAI-TKLUC. Conversely, activated RARa, GR, or c-ErbA can inhibit Fli-1-dependent transcription. The observed reciprocal repression, which occurs without binding of the proteins to one another's response elements, suggests an interaction at the level of the proteins themselves which can be considered as transcriptional interference. To investigate these observations further, we used deletion mapping studies to determine regions in RARa and Fli-1 responsible for the repressor function. The inhibitory eect of the RA-nuclear receptor can be observed when either endogenous or exogenous Fli-1 activates the E74-reporter plasmid. Interestingly, it appears that the DNA binding domain of RARa is necessary for ecient repressor activity. This is surprising because in gel mobility shift experiments RARa cannot bind to the Fli-1 binding site and suggests that the DNA binding domain is involved in a direct or mediated interaction with Fli-1 or that the DNA binding domain is required to achieve the proper conformation for the interaction. When we exchanged the RAR DNA binding domain with that from the GR, the resulting mutant also repressed eciently. This result indicates that the functions responsible for RAR-mediated repression are present in the GR and possibly in other nuclear hormone receptors, such as T 3 R.
Interference between two transcriptional regulating proteins can be achieved for example by (i) competition for a common or overlapping binding site, (ii) competition for a common factor(s) that mediate their action in the nucleus which was de®ned as squelching (Gill and Ptashne, 1988; Meyer et al., 1989) , and (iii) physical interaction between the proteins either direct or mediated by a`bridging' factor(s). The interference described between Fli-1 and the steroid hormone/ vitamin receptors does not require binding of Fli-1 and the receptors to the same template. The repression does not seem to depend on competitive binding of both factors to the same DNA nor does it require the DNA binding domain of Fli-1. The study of a set of Fli-1 deletion mutants demonstrates that the Nterminal region is responsible for repression. The Nterminal region of Fli-1 contains the amino-terminal transactivating helix-loop-helix domain which is known to be essential for full transactivating function, but does not contact DNA directly Siddique et al., 1993) . Weak homology with other helix-loop-helix transcription factors such as c-Myc and MyoD has led to the hypothesis that the 5' helixloop-helix domain in Ets proteins is involved in direct or mediated protein-protein interaction that facilitates transcriptional activation (Seth and Papas, 1990) . Our results suggest an additional function to the N-terminal region of Fli-1, namely faciliating repression of steroid hormone/vitamin-induced activation. Repression of transcriptional activity has been reported between PU.1/Spi-1 and GR nuclear receptors (Gauthier et al., 1993) . In contrast to results presented in this study, a mutant of GR lacking the hormone binding domain was as eective in repressing PU.1/Spi-1-dependent activity as wild-type GR, while our studies have shown that to some extent the hormone binding domain and amino terminus of RARa contribute to the repression activity. These dierences may be explained by the fact that Fli-1 and PU.1/Spi-1 proteins display marked dierences in the N-terminal regions interacting with the nuclear receptors (reviewed in Bassuk and Leiden, 1997) . No interference was found between other members of the Ets family, such as c-Ets-1, Elf-1 and GABP-a, and steroid hormone/vitamin receptors.
While deletion mapping and gel retardation assays have shown that interference between the two transcriptional regulating proteins was not achieved by competition for a common or overlapping binding site, we further investigated whether the interference was caused by competition for a common factor(s) that mediates their action in the nucleus. The DNA binding de®cient mutant of Fli-1 encoding only the N-terminal region was able to somehow titrate the RARa molecules, preventing a repression of Fli-1 transcriptional activation. Therefore, we conclude that Fli-1 and RARa are not competing for a common factor(s) that is functionally limiting in cells and necessary for transcriptional activation. In addition, gel retardation assays provided evidence that the interaction is dependent on the type of cells hosting the cotransfected Fli-1 and RARa molecules. Together with data obtained in our transfection experiments, we conclude that at least hematopoietic cells may contain a`bridging' factor(s) involved in complex formation and transcriptional interference. No retarded complex has been formed under our experimental conditions using nuclear extract from at least two nonhematopoietic cell lines overexpressing Fli-1 and RARa, which may indicate the absence of a`bridging' factor(s) in these cells. In addition, attempts were made to investigate potential direct interaction between Fli-1 and RARa using the twohybrid system developed in yeast. We were unable to detect a direct protein-protein interaction between Fli-1 and RARa in vitro. Results presented in this study are consistent with an indirect interaction between Fli-1 and the nuclear receptors. The presence of additional protein(s) seem to be required to stabilize the complex which are absent in mobility shift assays using in vitro translated proteins. The involvement of such factor(s) may explain why Fli-1 interferes with diverse members of the steroid hormone receptor superfamily. The absence of à bridging' factor(s) may explain why repression of RARa activity by exogenous Fli-1 cannot be observed in all cells tested, including the F9 line (data not shown). Further experiments are required to investigate the molecular mechanism of this interference.
It has been shown recently, that dierences between the Ets domains and sequences located next to this domain of Fli-1 and PU.1/Spi-1 (Watson et al., 1997) result in strikingly distinct DNA binding speci®cities (Watson et al., 1997) and correspondingly distinct transactivation of dierent target genes . For example, Fli-1 but not PU.1/Spi-1 binds to and transactivates the human glycoprotein IIb promoter . Consistent with these results in the literature, our GPIIb-TKLUC reporter was speci®cally activated by exogenous Fli-1 in K562 cells. The dierences in the DNA binding speci®city of Fli-1 and PU.1/Spi-1 are interesting given their non-overlapping involvement in leukemias induced by F-MuLV and SFFV, respectively. Their activation may alter the expression of dierent sets of target genes that contribute to the evolution of the leukemic phenotype. Several dierent human erythroleukemia cell lines show distinct levels of Fli-1 and PU.1/Spi-1 proteins and in some cells only one of the two Ets proteins is expressed Klemsz et al., 1993) , suggesting that aberrant expression of Fli-1 and PU.1/Spi-1 may be important for the formation of erythroleukemia in humans. In this study, we tested repression of the GPIIb-TKLUC reporter activity by steroid hormone/ vitamin receptors in K562, HEL and JK-1 erythroleukemia lines and Jurkat T-cell leukemia cells. In K562 cells, which expresses no endogenous Fli-1 Klemsz et al., 1993) , transcriptional activity of the GPIIb-TKLUC reporter was induced by exogenous Fli-1 and repressed by RARa. A similar repression pattern was detected by other exogenous hormone nuclear receptors in HEL, JK-1, and Jurkat cells. The data suggest that depending upon the expression patterns of Fli-1 and PU.1/Spi-1 in cells distinct or overlapping sets of target genes may be repressed by these hormone/vitamin receptors.
Much of developmental gene expression is governed at the level of transcription factors and a given hematopoietic lineage can be de®ned, in part, by the sum of active transcription factors expressed in the cells. The absence or repression of transcription factors may be as signi®cant as their presence for phenotypic changes. We have shown in this study that expression of the N-terminal region of Fli-1 blocks dierentiation of HL-60 cells and the decline of proliferation induced by physiological concentrations of RA. The response of these cells to supraphysiological concentration of RA (50 mM) may be mediated by residual RARs not interacting with Fli-1 proteins or via alternative pathways that are less aected by interference of Fli-1 and have a higher RA requirement. In murine macrophages, Fli-1 is optimally expressed in proliferating cells and any external signal that provides a stimulus for activation or dierentiation of the macrophages, including RA, rapidly down-regulates i-1 expression . Endogenous Fli-1 expressed in HL-60 cells is downregulated during RA-induced dierentiation three days post treatment (TG Darby, unpublished observations). Since RA and T 3 receptors seem to play a role in the regulation of normal erythroid dierentiation (Schroeder et al., 1992) , the oncogenic potential of deregulated Fli-1 may in part be related to its ability to repress steroid hormone/vitamin-induced transcriptional activity. Transcriptional interference between overexpressed Fli-1 and hormone/vitamin receptors may be involved in the blockage of the normal erythrodierentiation program by preventing the response of erythroblastic cells to hormone-or vitamin-induced signals. It is therefore possible that phenotypic changes seen in macrophages and erythroid cells during dierentiation require both, down-regulation of¯i-1 transcription and repression of Fli-1 protein by activated hormone/ vitamin receptors, and overexpressed Fli-1 in Friend leukemia blocks dierentiation and maintains the cells in a proliferative stage. Thus, the observation that Fli-1 and hormone/vitamin receptors can reciprocally repress one another's transcriptional activity provides an insight in the opposing eects of factors involved in stimulating erythroid cell growth and factors mediating dierentiation.
Materials and methods

Isolation of human Fli-1 cDNA
Human Fli-1 was cloned from a lgt11 cDNA library made from the Jurkat T cell line (Ho et al., 1990) . According to the murine Fli-1 cDNA , the primers 5'-TCTAGAGACGGGACTATTAAGGAGGCT-CTGTCTGTGGTGGAG-3' and 5'-AGATCTGGCTCA-GCTTGTCATAATTCATGTTTGGGCTTGCTC-3' were synthesized. These two primers were then used in the polymerase chain reaction (PCR). An approximately 1200 bp PCR product was cloned into pBluescript II SK + (Stratagene, Heidelberg, Germany) and partially dideoxy sequenced (Sanger et al., 1977) . This cloned PCR fragment was used as a probe to screen the same cDNA library. About 20 positive clones were isolated, and two of the phage inserts were subcloned into EcoRI site of pGEM-7Z(+) (Promega, Heidelberg, Germany). Dideoxy DNA sequencing reactions were performed by using a commercial kit (Promega, Heidelberg, Germany) . A 1823 bp cDNA sequence was obtained from the subclones.
Construction of Fli-1 expression plasmids
Oligonucleotides were synthesized on a DNA synthesizer (model 381A; Applied Biosystems, Inc., Forster City, CA). Several primers were synthesized according to the full-length human Fli-1 cDNA sequence: primer 210, 5' -TAGGGATCCGGCCCGACCAGCAGTCGCCTAGC-C-3'; primer 211, 5'-GGGAGATCTCTAGTAGTAGCT-GCCTAAGTGTGA-3'; primer 269, 5'-GAGGGATCC-GCCTATAATACAACCTCCCACACC-3'; primer 270, 5'-TAGGGATCCGTCAATGTGTGGAATATTGGGGGG-3'; primer 271, 5'-TAGGGTACCAGGGTTGGCTAGGC-GACTGCTGGT-3'; and primer 319, 5'-TAGGGTACC-GAGTCGTCCATGTACAAGTACCCT-3'. The primers 210 and 211 were used to amplify the DNA fragments encoding the Ets domain and the carboxy-terminal region of Fli-1 (named 3'Fli-1). Primer 269 and primer 211 were used to amplify the extended 3'Fli-1 fragment including the carboxy-terminal region, Ets domain and adjacent Nterminal amino acids (named e3'Fli-1). Primer 270 and 271 were used to amplify the truncated 5'Fli-1 fragment encoding the N-terminal region of Fli-1. Construct SV40LT5'Fli-1 was created by subsequent ligation of the 5'-Fli-1 PCR fragment downstream of an SV40 nuclear translocation signal (Kalderon et al., 1984) in pRS expression vector (Giguere et al., 1986) . Plasmid SV40LTFli-1Dets, lacking the Ets domain, was created using primer 270 and 271 to amplify the 5'Fli-1 fragment and primer 319 and primer 211 to amplify the carboxyterminal region. Fusion of the Fli-1 amino-terminal sequences to the carboxy-terminal sequences was obtained by digestion of the two PCR fragments with KpnI and religation of the two KpnI fragments. This fused fragment was ligated to the SV40 nuclear translocation signal, digested with BamHI and BglII, and ligated into the BamHI/BglII sites of pSG5 (Stratagene, Heidelberg, Germany). The DNA binding-de®cient mutant Fli-1W321R was generated by oligonucleotide site-directed mutagenesis. Full length Fli-1 was cut out from pGEM-7Z(+) and cloned between XhoI and ClaI sites of pSP73 (Promega, Heidelberg, Germany) to generate the plasmid pSPhFli-1. Full-length wild-type Fli-1 was digested with EcoRI and HindIII to obtain a 657 bp fragment of Fli-1 which includes the Ets domain. This fragment was inserted in EcoRI/HindIII-restricted M13mp19. Mutation of the wild-type codon TGG (W-321) into codon CGG (R) was carried out on the corresponding single-stranded viral DNA, using the Amersham site-directed mutagenesis kit and the mutagenic oligonucleotide 5'-GCCAGGCG-CCGGGGGCAGCGG-3'. The mutated fragment was religated into EcoRI/HindIII-restricted full-length Fli-1 to create pSPhFli-1mut. The empty parental plasmid, lacking the Fli-1 coding sequence was named DFli-1.
The PCR reactions contained 1 mg of each primer, 10 ng of plasmid containing full-length Fli-1 cDNA, 10 mM Tris (pH 8.3), 1.5 mM MgCl 2 , 50 mM KCl, 2 mM dithiothreitol, 0.01% gelatin, 200 mM of each dXTP and 2.5 units of Taq polymerase (Promega, Heidelberg, Germany). PCR products obtained after 27 cycles of ampli®cation (2 min at 958C, 1.5 min at 558C, 2 min at 728C) were digested with BamHI and BglII and cloned into the BamHI/BglII sites of pSG5. Full-length wild-type was cut out from pSPhFli-1 and mutated (W?R) human Fli-1 was cut out from pSPhFli1mut and cloned into the BglII sites of the expression vector pSG5. The Fli-1 constructs were dideoxy sequenced to con®rm the orientation. The schematic illustration of dierent forms of Fli-1 proteins are shown in Figure 3a .
Construction of other expression plasmids
The RARa deletion plasmids were constructed as follows. An EcoRI fragment from pSG5 (Brand et al., 1988) , containing the human RARa coding region, was ligated into the EcoRI site of pBluescript II KS + (Stratagene, Heidelberg, Germany), generating pKSRARa5. A region of human RARa encoding the ®rst 183 amino acids was ampli®ed from pKSRARa5 with the primer pair 5' -G G C GAAT TCCCC TGCCAGACTGTCTGCCTC -3' and 5' -GCGAGATCTCTCCGGCGTCAGCGTGTA -3' and was digested with EcoRI and BglII. The digested PCR fragment was ligated into the EcoRI/BglII sites of pSG5 to yield RARaDEF.
To generate RARaDAB, DNA encoding amino acids 84 ± 186 was ampli®ed from pKSRARa5, with primers 5' -GCGGAATTCATCTACAAGCCTTGCTTTGTCTGT-3' and 5'-CACGCGCTTCTCAATGAGCTCCCCCACCTC-3', ending at the internal SstI site. The PCR product was digested with EcoRI and SstI and ligated along with a SstI/ BamHI fragment from pKSRARa5 (encoding the carboxy terminus). The fragment encoding the RARa CDEF region, including the stop codon, was released by EcoRI/BamHI digestion and subcloned into the EcoRI/BamHI site of pSG5.
To construct RARaDC, a region encoding the ®rst 88 amino acids was ampli®ed from pKSRARa5 with primers 5'-GGCGAATTCCCCTGCCAGACTGTCTGCCTC-3' and 5'-GCGCTGCAGGCAAGGCTTGTAGATGCGGGG-3' and was digested with EcoRI and PstI. This fragment was ligated with the PstI/BamHI fragment from pKSRARa5, beginning with the nucleotides at the internal most proximal 5' PstI site of RARa and encoding the 3' end of the coding region. The obtained EcoRI/BamHI fragment was ligated into the EcoRI/BamHI sites of pSG5 to yield RARaDC.
To construct RARaDABEF, encoding the DNA binding region, DNA encoding amino acid 84 to 183 of RARa was ampli®ed from plasmid pKSRARa5 with primers 5' -GCGGAATTCATCTACAAGCCTTGCTTTGTCTGT-3' and 5 ' -GCGAGATCTCTCCGGCGTCAGCGTGTA -3 '. This PCR fragment was digested with EcoRI and BglII and ligated along with a EcoRI/BglII fragment of pSG5.
For the construction of RAR-GR-RAR, a construct RARaXo.Xa. was prepared by site-directed mutagenesis by creating a XhoI and XbaI site, respectively, at the beginning and the end of the C region of RARa, resulting in two additional amino acids (Leu-Glu) at the end of the B region and in two additional amino acids (Ser-Arg) at the beginning of the D region. The DNA binding region of GR, spanning amino acid 404 to 491 was ampli®ed from pGR108 (Hollenberg et al., 1985) with primers 5'-TAACTC-GAGTCTCCTCCATCCAGCTCC-3' and 5'-GGGTCTA-GATCGAGCTTCCAGGTTCAT-3' and digested with XhoI and a XbaI. The XhoI/XbaI RARa C-region fragment was replaced by the XhoI/XbaI fragment, encoding the GR DNA binding region to construct RAR-GR-RAR in pSG5. The sequence of these constructs were con®rmed according to Sanger et al. (1977) . The schematic illustration of structure of RARa proteins are shown in Figure 4a .
Expression vectors encoding hGR (Giguere et al., 1986) , cErbA/T 3 Ra under the transcriptional control of the Rous sarcoma virus (RSV) long terminal repeat (Damm et al., 1989) , PU.1/Spi-1 in the pECE vector (Klemsz et al., 1990) , and human retinoic X receptor (hRXR) a (Mangelsdorf et al., 1990) have been described. The RSV-hGH expression plasmid (Nicol's Institute, CA) contains the TK promoter fused to the human growth hormone (hGH) gene.
Construction of reporter plasmids
RARb2 promoter construct was derived from human RARb2 promoter sequences contained within plasmid pD1 (de TheÂ et al., 1990). pD1 was digested with EcoRI and the 5 kb promoter fragment was ligated into pBlue-script II SK + (Stratagene, Heidelberg, Germany) to yield pBSKR3. pBSKR3 was digested with HindIII and SacI and the 5 kb fragment was ligated into the HindIII/SacI sites of pXP2 (Nordeen, 1988) .
Plasmids (b2RARE) 3 -TKLUC (de TheÂ et al., 1990) , PAL 2 -TKLUC (Nagaya and Jameson, 1993) , and GRE-TKLUC (R Zand, National Institutes of Health) contain hormone response elements cloned upstream of the minimal TK promoter (7109 to +52) in the luciferase expression vector pT109LUC. The pT109LUC vector derived from pXP2 (Nordeen, 1988) . (b2RARE) 3 -TKLUC contains three copies of the RARE sequence 5'-GGGTAGGGTTCACC-GAAAGTTCACTCG-3' from the RARb2 promoter, PAL 2 -TKLUC contains two copies of the T 3 response element (PAL) 5'-TTTGGCTCTGGAGGTCATGACCT-3', and GRE-TKLUC contains one copy of the GR response element (GRE) 5'-GCACCCGGTACACTGTGTCCTCC-CGCT-3' . The reporter plasmid ApoAI-TKLUC was obtained by ligating the synthetic RARE sequence 5'-GATCAGGGCAGGGGTCAAGGGTTCAGT-GATC-3' of the ApoAI promoter (Ladias and Karathanasis, 1991) into the HindIII site of pT109LUC. The reporter construct (E74) 4 -TKLUC was made by cloning four copies of E74 target sequence 5'-AATAACCGGAAGTAACTC-3' into the HindIII site of pT109LUC. Plasmid GPIIb-TKLUC contains a Fli-1 DNA binding site of the human glycoprotein IIb promoter . The reporter construct was obtained by ligating the sequence 5'-TCAGCATCCTCCACAGGAAGTCTTT-3' into the HindIII site of pT109LUC. The Sp1-TKLUC construct, which contains a Sp1-binding site has been described (Dynan and Tjian, 1983) .
Transfections and luciferase assays
Tissue culture plasticware was purchased from Falcon (Becton Dickinson Labware, NJ). Transfection of plasmid DNA into the erythroleukemia lines RM10, HEL, JK-1, K562, Jurkat T-cell leukemia, HL-60 myeloblastic leukemia, and F9 teratocarcinoma line was performed using the standard calcium phosphate coprecipitation technique (Gorman et al., 1982) . F9 cells were grown in DMEM and the other cells were maintained in RPMI. All media (Gibco, Karlsruhe, Germany) were supplemented with 10% fetal calf serum (Gibco, Karlsruhe, Germany). Twenty-four hours before transfection the cells were seeded at a density of 6610 5 cells/60 mm dish. Three mg of each of the reporter plasmids and 2 mg of a RSV-hGH expression plasmid (Nicol's Institute, CA) were used in the experiments. In cotransfection experiments, 0.5 mg of the various expression constructs were used and indicated in the Figure legends as +. One set of cotransfection experiments was performed with two expression constructs, 0.5 mg of RARa and 0.5 mg of RXRa , and 3 mg of reporter plasmids. When dierent amounts of expression plasmid DNA were cotransfected the numbers in mg of DNA are indicated in the legends. To keep the amount of transfected DNA constant, the total amount of transfected DNA was adjusted to 20 mg with pBluescript SK + . Cells were incubated in the presence or absence of RA (50 nM), T 3 (1 mM) and dexamethasone (DEX; 1 mM), respectively. These drugs were purchased from Sigma Chemical Co. (Munich, Germany). The following day, the calcium phosphate-DNA precipitate was washed away and fresh medium containing RA, T 3 or DEX was added for an additional 24 h. Extracts were prepared and assayed as described (de Wet et al., 1987) with minor modi®cations described by (Pahl et al., 1993) . Data are shown in relative light units per ng of growth hormone. Growth hormone concentrations were determined by radioimmunoassay (Nicol's Institute, CA). All experiments were repeated at least three times. Western immunoblot analysis revealed that the various Fli-1 and RARa mutants were wellexpressed in similar amounts in all cell lines and experiments.
For generating HL-60 cells expressing the N-terminal or C-terminal region of Fli-1, the constructs SV40LT5'Fli-1, e3'Fli-1, or parental pSG5 were cotransfected with pHook-1 (Invitrogen, NV Leek, The Netherlands). Using the CaptureTec System (Chestnut et al., 1996) (Invitrogen, NV Leek, The Netherlands) we selected a homogeneous population of transfected cells expressing the SV40LT5'Fli-1, e3'Fli-1, and pSG5 construct, respectively. Western immunoblot analysis revealed that wild-type and Fli-1 mutants were well-expressed in similar amounts in the cells.
Proliferation assay
Cell proliferation was measured as described previously (Celada and Maki, 1992) with some modi®cations. After electroporation and selection by the Capture-Tec System. HL-60 cells (1610 6 ) were incubated in 24-well plates in 1 ml of media in the presence or absence of 50 nM or 50 mM RA. [
3 H]thymidine (1.0 mCi/ml) was added to the media at 0 h and again at 36 h with 1 ml of fresh media containing 50 nM and 50 mM RA. Cells were incubated for 12, 24, 48, and 96 h at 378C and then the media was removed and cells were ®xed in methanol. After three washes in 10% TCA, cells were solubilized in 1% SDS and 0.5 M NaOH. Radioactivity was counted by liquid scintillation. In some experiments, cells were counted with a Coulter counter after 4 and 6 days. Each experiment was performed at least three times and the results are expressed as the mean+s.d. Statistical analysis was performed using the Student's paired t test.
For cell morphology studies the colonies were maintained in culture in the absence or presence of 50 nM or 50 mM RA for 6 days. The cultures were stained with Wright-Giemsa and examined by light microscopy.
Preparation of nuclear extracts
Nuclear extracts were prepared from transient transfected RM10, HL-60, F9, and HeLa cells overexpressing Fli-1 and RARa. Cells were cultured for 24 h in the presence of 50 nM RA and nuclear extracts were prepared by the procedure of (Schreiber et al., 1989) . In vitro transcribed and translated proteins were prepared using TNT Coupled Reticulocyte Lysate System supplied by Promega (Heidelberg, Germany).
Electrophoretic mobility shift assays (EMSAs)
EMSAs were performed as previously described with some modi®cations by (Pahl et al., 1993) . Oligonucleotides puri®ed by electrophoresis were annealed (50 mg of each), endlabeled with g-[ 32 P]dATP, and the unincorporated label separated by passage through a DNAgrade Sephadex G-50 column (Pharmacia Europe, Freiburg, Germany). 1.5 mg of in vitro translated protein or 5 mg of nuclear extract were incubated on ice for 30 min with 10 000 c.p.m. (200 ± 300 ng) of probe in a 30 ml reaction mixture containing 12 mM HEPES (pH 7.9), 0.5 mM EDTA, 5 mM MgCl 2 , 10% (vol/vol) glycerol, 1 mM dithiothreitol (DTT), 60 mM KCl, 0.05% NP40, and 21 mg of poly (dI ± dC) (Pharmacia Europe, Freiburg, Germany). Mixtures were preincubated on ice for 5 ± 10 min before addition of the probe. In competition experiments, unlabeled annealed oligonucleotides (200-fold excess) of self or nonspeci®c DNA were added together with poly (dI ± dC) for 15 min before the addition of the probe, followed by a further 15 min incubation on ice. After incubation, the samples were fractionated at 48C on 5% polyacrylamide gels (acryla-
